4
Changes in Ownership
PROTHENA CORP PUBLIC LTD CO Filed Acc 0001140361-23-028870
Chief Scientific Officer sold 19,000 shares at an average $71.06 ($1,350,224)
- Chief Scientific Officer acquired 19,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Option exercise 10b5-1 | +15,000 | $29.81 | $447,150 | 15,000 | D: show line 1 in the form |
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Option exercise 10b5-1 | +4,000 | $12.15 | $48,600 | 19,000 | D: show line 2 in the form |
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Sale 10b5-1 | −2,943 | $70.02 | $206,061 | 16,057 | D: show line 3 in the form |
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Sale 10b5-1 | −12,004 | $70.99 | $852,181 | 4,053 | D: show line 4 in the form |
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Sale 10b5-1 | −3,759 | $71.96 | $270,479 | 294 | D: show line 5 in the form |
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Sale 10b5-1 | −294 | $73.14 | $21,503 | 0 | D: show line 6 in the form |
| Open-market sales · 19,000 sh · avg $71.06 · $1,350,224 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 0 | D: show line 7 in the form | |||||
| Zago Wagner M. Chief Scientific Officer | 2023-06-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 66,000 | D: show line 8 in the form |
Loading xslF345X04/form4.xml…